.blurhash-client-img { display: none !important; }

Clinical outcomes and safety profile of emicizumab and other treatment options for the management of children and adults with severe haemophilia A in the UAE: A retrospective study at two tertiary hospitals

The Journal of Haemophilia Practice

Volume 12 (2025): Issue 1 (January 2025)

By: Haydar Al Rufaye , Laila Alkhouli, Haytham Al Jabour, Hani Yousif Osman, Muhammad Ibraham Khanani, Muhammad Faisal Khanani and Nasser Al Azein

Open Access

|Oct 2025

Authors

Haydar Al Rufaye

Hrufaye@seha.ae

Tawam Hospital, Al Ain, United Arab Emirates

Laila Alkhouli

Pediatric Institute, Cleveland Clinic Foundation, Cleveland, United States

Haytham Al Jabour

Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates

Hani Yousif Osman

Tawam Hospital, Al Ain, United Arab Emirates

Muhammad Ibraham Khanani

Burjeel Royal Hospital, Asharej, Al Ain, United Arab Emirates

Muhammad Faisal Khanani

Tawam Hospital, Al Ain, United Arab Emirates

Nasser Al Azein

Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates

DOI: https://doi.org/10.2478/jhp-2025-0013 | Journal eISSN: 2055-3390

Journal RSS Feed

Language: English

Page range: 104 - 110

Published on: Oct 1, 2025

Published by: Haemnet Ltd

In partnership with: Paradigm Publishing Services

Publication frequency: 1 issue per year

Keywords:

Health-related quality of life,

Severe haemophilia A,

United Arab Emirates

Related subjects:

Basic medical science,

Basic medical science, other,

Clinical medicine,

Clinical medicine, other,

© 2025 Haydar Al Rufaye, Laila Alkhouli, Haytham Al Jabour, Hani Yousif Osman, Muhammad Ibraham Khanani, Muhammad Faisal Khanani, Nasser Al Azein, published by Haemnet Ltd
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 12 (2025): Issue 1 (January 2025)Next article